Citigroup’s Solid Biosciences SLDB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.48M | Buy |
148,432
+79,056
| +114% | +$599K | ﹤0.01% | 3157 |
|
|
2026
Q1 | $500K | Buy |
69,376
+65,869
| +1,878% | +$423K | ﹤0.01% | 3547 |
|
|
2025
Q4 | $19.8K | Sell |
3,507
-2,685
| -43% | -$14.6K | ﹤0.01% | 4874 |
|
|
2025
Q3 | $38.2K | Sell |
6,192
-46,182
| -88% | -$270K | ﹤0.01% | 4570 |
|
|
2025
Q2 | $255K | Buy |
52,374
+34,291
| +190% | +$121K | ﹤0.01% | 3950 |
|
|
2025
Q1 | $66.9K | Buy |
18,083
+428
| +2% | +$1.83K | ﹤0.01% | 4790 |
|
|
2024
Q4 | $70.6K | Buy |
17,655
+1,045
| +6% | +$5.74K | ﹤0.01% | 4973 |
|
|
2024
Q3 | $116K | Buy |
16,610
+11,569
| +229% | +$93.8K | ﹤0.01% | 4701 |
|
|
2024
Q2 | $28.6K | Sell |
5,041
-42,671
| -89% | -$382K | ﹤0.01% | 4885 |
|
|
2024
Q1 | $636K | Buy |
+47,712
| New | +$446K | ﹤0.01% | 3403 |
|
|
2022
Q4 | – | Sell |
-98
| Closed | -$1K | – | 5939 |
|
|
2022
Q3 | $1K | Sell |
98
-56
| -36% | -$565 | ﹤0.01% | 5685 |
|
|
2022
Q2 | $1K | Sell |
154
-228
| -60% | -$2.37K | ﹤0.01% | 6087 |
|
|
2022
Q1 | $7K | Sell |
382
-1,332
| -78% | -$23.5K | ﹤0.01% | 5703 |
|
|
2021
Q4 | $45K | Buy |
1,714
+1,245
| +265% | +$38K | ﹤0.01% | 5121 |
|
|
2021
Q3 | $17K | Buy |
469
+33
| +8% | +$1.4K | ﹤0.01% | 5300 |
|
|
2021
Q2 | $24K | Buy |
436
+65
| +18% | +$4.29K | ﹤0.01% | 5203 |
|
|
2021
Q1 | $31K | Sell |
371
-260
| -41% | -$28.8K | ﹤0.01% | 4991 |
|
|
2020
Q4 | $72K | Buy |
631
+243
| +63% | +$15.4K | ﹤0.01% | 5792 |
|
|
2020
Q3 | $12K | Sell |
388
-65
| -14% | -$2.49K | ﹤0.01% | 6512 |
|
|
2020
Q2 | $20K | Sell |
453
-71
| -14% | -$2.95K | ﹤0.01% | 6623 |
|
|
2020
Q1 | $19K | Sell |
524
-51
| -9% | -$2.52K | ﹤0.01% | 6737 |
|
|
2019
Q4 | $38K | Sell |
575
-950
| -62% | -$105K | ﹤0.01% | 6538 |
|
|
2019
Q3 | $237K | Buy |
1,525
+2
| +0.1% | +$226 | ﹤0.01% | 5018 |
|
|
2019
Q2 | $131K | Buy |
1,523
+26
| +2% | +$2.84K | ﹤0.01% | 5626 |
|
|
2019
Q1 | $207K | Sell |
1,497
-3,240
| -68% | -$812K | ﹤0.01% | 5065 |
|
|
2018
Q4 | $1.9M | Buy |
4,737
+4,500
| +1,899% | +$2.12M | ﹤0.01% | 2726 |
|
|
2018
Q3 | $168K | Buy |
237
+123
| +108% | +$77.3K | ﹤0.01% | 5426 |
|
|
2018
Q2 | $61K | Sell |
114
-2
| -2% | -$615 | ﹤0.01% | 6133 |
|
|
2018
Q1 | $13K | Buy |
+116
| New | +$39.2K | ﹤0.01% | 6942 |
|
Other funds holding SLDB
SL
Citigroup's SLDB Position: Q2 2026 in Review
Citigroup increased its Solid Biosciences (SLDB) stake by 114% in Q2 2026, buying an estimated $599K and bringing the position to 148,432 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #3157.
Citigroup first reported a position in SLDB in Q1 2018 and has held it in 29 quarters since. The position peaked at $1.9M in Q4 2018. 156 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.
- Citigroup held 148,432 shares of Solid Biosciences worth $1.48M as of Q2 2026.
- Citigroup bought 79,056 Solid Biosciences shares in Q2 2026, an estimated $599K.
- Solid Biosciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3157 holding.
- Citigroup first reported a position in Solid Biosciences in Q1 2018 and has held it in 29 quarters since.
- Citigroup's Solid Biosciences position peaked at $1.9M in Q4 2018.
- 156 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.